N-(tert-butyloxycarbonyl)-3-fluoro-5-(4-morpholinyl)aniline | 942999-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-(tert-butyloxycarbonyl)-3-fluoro-5-(4-morpholinyl)aniline
• 英文别名: N-(tert-butoxycarbonyl)-3-fluoro-5-(morpholin-4-yl)aniline；tert-butyl N-[3-fluoro-5-(morpholin-4-yl)phenyl]carbamate；tert-butyl N-(3-fluoro-5-morpholin-4-ylphenyl)carbamate
• CAS: 942999-25-9
• 化学式: C₁₅H₂₁FN₂O₃
• 分子量: 296.342
• InChiKey: FTTUHVDOQJRWTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(tert-butyloxycarbonyl)-3-fluoro-5-(4-morpholinyl)aniline 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 3-fluoro-5-(4-morpholinyl)aniline hydrochloride
  参考文献：
  名称：

  Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

  摘要：

  Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.

  DOI：

  10.1021/jm701359z
• 作为产物：
  描述：

  3-fluoro-5-(4-morpholinyl)benzoic acid 在 二苯基膦叠氮化物 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 19.0h， 生成 N-(tert-butyloxycarbonyl)-3-fluoro-5-(4-morpholinyl)aniline
  参考文献：
  名称：

  Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

  摘要：

  Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.

  DOI：

  10.1021/jm701359z

文献信息

• WO2007/72041
  申请人：——

  公开号：——

  公开（公告）日：——